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Background: Although Toxoplasma gondii infection is normally asymptomatic, severe cases of toxoplasmosis may
occur in immunosuppressed patients or congenitally infected newborns. When a fetal infection is established, the
recommended treatment is a combination of pyrimethamine, sulfadiazine and folinic acid (PSA). The aim of the
present study was to evaluate the efficacy of azithromycin to control T. gondii infection in human villous explants.
Methods: Cultures of third trimester human villous explants were infected with T. gondii and simultaneously
treated with either PSA or azithromycin. Proliferation of T. gondii, as well as production of cytokines and hormones
by chorionic villous explants, was analyzed.
Results: Treatment with either azithromycin or PSA was able to control T. gondii infection in villous explants. After
azithromycin or PSA treatment, TNF-α, IL-17A or TGF-β1 levels secreted by infected villous explants did not present
significant differences. However, PSA-treated villous explants had decreased levels of IL-10 and increased IL-12 levels,
while treatment with azithromycin increased production of IL-6. Additionally, T. gondii-infected villous explants
increased secretion of estradiol, progesterone and HCG + β, while treatments with azithromycin or PSA reduced
secretion of these hormones concurrently with decrease of parasite load.
Conclusions: In conclusion, these results suggest that azithromycin may be defined as an effective alternative drug
to control T. gondii infection at the fetal-maternal interface.
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Toxoplasma gondii is an obligate intracellular protozoan
parasite that infects a wide range of hosts, including
humans. During pregnancy, primary infection can result
in the vertical transmission of T. gondii tachyzoites, po-
tentially having severe consequences for the fetus, such
as retinochoroiditis as well as hydrocephalus and intracra-
nial calcification [1]. The risk of fetal infection by T. gondii
increases as pregnancy progresses [2,3]. Nevertheless, the
consequences of fetal infection are more severe the earlier
infection occurs during pregnancy [4].* Correspondence: eloisa@umuarama.ufu.br
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article, unless otherwise stated.A combination of pyrimethamine, sulfadiazine and folinic
acid (PSA) or spiramycin are standard care for treatment of
toxoplasmosis in cases of fetal infection [5,6]. Treatment
with spiramycin is administered immediately after diagnosis
of maternal infection [7], and since this macrolide does
not cross placenta, it is not suitable for treatment of fetal
infections [8]. PSA is the recommended combination for
pregnant women treatment who acquire the infection
after 18 weeks of gestation. However, pyrimethamine is
potentially teratogenic and should not be used in the first
trimester of pregnancy [8]. Pyrimethamine is a folic acid
antagonist and its use in pregnancy has been associated
with increased risk of neural tube defects [9]. This drug is
potentially toxic, usually causing gradual dose-related
bone marrow depression, chromosomal damage and
mutagenicity [9,10]. Folinic acid is used for reduction
and prevention of hematological toxicities caused byntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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toxoplasmosis, such as trimethoprim-sulfamethoxazole or
clindamycin, have shown activity in vitro and in mouse
models, but clinical studies to establish their efficacy have
not been conclusive [10]. Thus, there is an urgent need
for more effective and non-toxic chemotherapeutic agents
and novel drug targets to be identified for treatment of
T. gondii infection during pregnancy.
Azithromycin is a semisynthetic azalide antibiotic that
is structurally related to erythromycin, but has a broader
spectrum of antibacterial activity and a more favorable
pharmacokinetic profile. Furthermore, administration is
required only once per day [11-13]. Azithromycin also
inhibits protein synthesis in the plasmodial apicoplast
and, thus, has activity against both Plasmodium falciparum
and P. vivax [12]. Azithromycin is widely used for the treat-
ment of community-acquired pneumonia and chlamydia
during pregnancy, and has been safely administered in
all trimesters of gestation [14,15]. Studies have shown
that animals receiving 60 times the recommended dose
of azithromycin for humans do not have decreased fer-
tility or demonstrated harmful effects on the fetus [16].
Given that azithromycin is considered safe during
pregnancy and the fact that it may have activity against
pathogens, such as Plasmodium and Toxoplasma, it has
been suggested as a candidate for intermittent preventive
treatment during pregnancy [7,17]. Previous studies have
shown that azithromycin treatment in pregnant Calomys
callosus and human trophoblast cells (lineage BeWo) was
able to control T. gondii infection, suggesting that it may be
an alternative drug for prevention of congenital infection
[18,19]. Additionally, azithromycin has anti-inflammatory
properties through modulating the production of proin-
flammatory cytokines that are produced during T. gondii
infection [20].
Thus, the aim of the present study was to evaluate the
efficacy of azithromycin in the control of T. gondii in-
fection in third trimester human villous explants cul-
tures compared to traditional therapy (PSA).
Methods
Placental samples
Placental tissues were obtained from 24 women after elective
cesarean section deliveries (36 to 40 weeks of pregnancy).
Exclusion criteria included pre-eclampsia, chronic hyper-
tension, infectious disease including toxoplasmosis,
chorioamnionitis, chronic renal disease, cardiac disease,
connective tissue disease, pre-existing diabetes mellitus
and gestational diabetes mellitus. Placental tissues were
placed in ice-cold sterile phosphate-buffered saline (PBS),
pH 7.2, to remove excess blood then aseptically dissected
using a stereomicroscope to remove endometrial tissue
and fetal membranes up to 1 h after collection. Float-
ing terminal chorionic villous explants containing fiveto seven free tips per explant were collected as described
previously [21,22]. Explants were added to 96-well plates
(one per well) and cultured in complete medium containing
RPMI 1640 medium (Cultilab, Campinas, SP, Brazil)
supplemented with 10% fetal bovine serum (FBS) (Cultilab),
100 U/mL penicillin, and 100 μg/mL streptomycin
(Sigma-Aldrich Co., St. Louis, MO, USA) for 24 h at
37°C and 5% CO2.
Parasites
Tachyzoites from T. gondii 2 F1 strain, which constitutively
express cytoplasmic β-galactosidase and are derived from
the RH strain, were maintained by serial passages in BeWo
cells in RPMI medium supplemented with penicillin,
streptomycin and 2% FBS at 37°C and 5% CO2. T. gondii
2 F1 was a gift from Dr. Vern Carruthers, Medicine School
of Michigan University (USA).
Antibiotics
Macrolide azithromycin (Biofarma, Uberlândia, MG, Brazil)
or a drug combination consisting of pyrimethamine
(Daraprim® - Farmoquímica, Rio de Janeiro, RJ, Brazil),
sulfadiazine (Suladrin®- Laboratório Catarinense, Joinville,
SC, Brazil) and folinic acid (Genix, Anápolis, GO, Brazil)
(PSA) were dissolved in culture medium to a concentration
of 5000 μg/mL (stock solution). Different drug concentra-
tions were prepared by diluting the stock solution and used
for treatment of villous explants.
Treatments
First, villous explants were infected with T. gondii 2 F1
strain tachyzoites (1 × 106 parasites per well) and incu-
bated for 48 h. Next, villous explants were washed with
complete medium to remove non-adhered parasites and
treated for an additional 24 h with different concentra-
tions of azithromycin (200, 1000 or 5000 μg/mL) or PSA
as follows: 200, 1000 or 5000 μg/mL for pyrimethamine;
150, 750 or 3750 μg/mL for sulfadiazine; and 30, 150 or
750 μg/mL for folinic acid, as previously established [23].
Uninfected/untreated villous explants or infected/untreated
villous explants (NT) were cultured with complete medium
only and included as experimental controls. After, culture
supernatants were collected and stored at −70°C for
measurement of cytokines or nitrite at a later time. Villous
explants were collected for morphological analysis, im-
munohistochemistry, or analysis for T. gondii intracel-
lular proliferation using a colorimetric β-galactosidase
assay as previously described [24]. T. gondii intracellu-
lar proliferation data were expressed as the number of
tachyzoites calculated in relation to the standard curve of
2 F1 strain tachyzoites ranging from 1 × 106 to 15.625 × 103
total parasites.
In another set of experiments, parasites were pre-treated
with antibiotics. Briefly, 2 F1 strain tachyzoites were treated
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1000 μg/mL) or PSA (50, 100, 200 or 1000 μg/mL for pyri-
methamine; 37.5, 75, 150 or 750 μg/mL for sulfadiazine and
7.5, 15, 30 or 150 μg/mL for folinic acid), diluted in culture
complete medium for 1 h at 37°C in a CO2 incubator.
Afterwards, parasites were placed in 96-well tissue culture
plates containing previously collected villous explants.
Untreated parasites (NTp) remained for 1 h in complete
medium under the same conditions as treated parasites
and were used to infect villous explants. After 72 h, villous
explants were collected for T. gondii proliferation assays
according Teo et al. [24].
T. gondii intracellular proliferation assay
The villous explants were submitted to a colorimetric
β-galactosidase assay in order to analyze the T. gondii
intracellular proliferation [24] with minor modifications.
Briefly, villous explants were homogenized in radioim-
munoprecipitation assay buffer (RIPA) [50 mmol/L
Tris hydrochloride, 150 mmol/L NaCl, 1% (v/v) Triton
X-100, 1% (w/v) sodium deoxycholate, and 0.1% (w/v)
SDS; pH 7.5] plus protease inhibitor cocktail tablets
(Roche Diagnostics GmbH, Mannheim, Germany). The
homogenate was centrifuged at 15,000 x g for 15 minutes
at 4°C, the supernatants were used for protein content
measurement using the Bradford method [25] and
100 μg/mL of total protein was used to perform the
colorimetric β-galactosidase assay. Then, the total pro-
tein (100 μg/mL) was incubated with 160 μL of assay
buffer (100 mM phosphate buffer, pH 7.3, 102 mM mer-
captoethanol and 9 mM MgCl2) and 40 μL 6.25 mM
CPRG (chlorophenol red-β-D-galactopyranoside; Roche,
Indianapolis, IN) for 30 min. The enzymatic activity of
β-galactosidase was measured at an absorbance of 570 nm
using a kinetic plate reader (Titertek Multiskan Plus, Flow
Laboratories, McLean, VA, USA).
Toxicity assay
Culture supernatants were collected and measurement
of lactate dehydrogenase (LDH) was immediately performed
in order to determine cytotoxicity of tested drugs to in-
fected human villous explants. Measurement of LDH
released from the cytosol of lysed cell membranes into
the supernatant was performed using a commercial
diagnostic kit according to manufacturer instructions
(LDH Liquiform, LabtestDiagnostica S.A., Lagoa Santa,
MG, Brazil). The method used is based on consump-
tion and decrease of absorption of NADH at 340 nm,
which was measured in a DU-70 spectrophotometer
(Beckman, Brea, CA, USA) for 3 min at 37°C. The data
were expressed in U/mL of enzyme activity. The negative
control (uninfected control) was determined by spon-
taneous LDH released from uninfected villous explants.
Maximum LDH released, defined as positive control(total cell lysis), was determined by adding 0.2% Triton
X-100 to explants. In parallel, cytokine and hormone
levels were measured in supernatants. The doses of 200
and 1000 μg/mL for azithromycin or pyrimethamine;
150 and 750 μg/mL for sulfadiazine; and 30 to 150 μg/mL
for folinic acid were chosen for this latter purpose accord-
ing to toxicity results. All subsequent experiments were
performed using these drug concentrations. Hereafter, PSA
concentrations will be denoted based on the concentration
of pyrimethamine.
Morphological analysis and immunohistochemistry
To verify the integrity of villous explants and immunolo-
calization of parasites, fragments of placental explants
were fixed in 10% buffered formalin, dehydrated in increas-
ing alcohol concentrations, and embedded in paraffin. Sec-
tions with 4 μm were placed on glass slides and subjected
to immunohistochemical analysis [22]. For antigen retrieval,
sections were covered with trypsin solution (0.05% trypsin
and 0.1% calcium chloride (Sigma-Aldrich Co.) for 30 min
at 37°C. Explant sections were incubated in 5% acetic acid
at room temperature in order to block endogenous phos-
phatase activity. Next, sections were incubated overnight at
4°C with hyperimmune rabbit anti-T. gondii serum (1:100).
Biotinylated goat anti-rabbit IgG (1:600, Sigma-Aldrich Co.)
was used as secondary antibody, and the reaction was
developed with fast red naphthol (Sigma-Aldrich Co.).
Samples were counterstained with Harris’s hematoxylin
and examined under a light microscope (BX40, Olympus,
Tokyo, Japan).
Cytokine and nitrite assays
Villous explant culture supernatants were analyzed for
IL-12, TNF-α, IL-10 and TGF-β1 concentrations using
a sandwich ELISA according to the manufacturer’s in-
structions (R&D Systems, BD Biosciences, San Diego,
CA, USA). Cytokine concentration was determined by
extrapolation from a standard curve obtained from known
concentrations of the respective recombinant cytokines.
Optical density was measured at 450 nm with a micro-
plate reader (Titertek Multiskan Plus, Flow Laboratories,
McLean, VA, USA). The limit of detection of the assays
was 7.8 pg/mL for both TNF- α and IL-12, 62.5 pg/mL for
IL-10, and 31.3 pg/mL for TGF- β1.
Additionally, human cytokines (IL-2, IFN-γ, IL-6, IL-4
and IL-17A) were quantified using a cytometric bead
arrayTM (CBA; BD Biosciences) according to the manu-
facturer’s instructions. Samples were analyzed using a
BDTM flow cytometer (FACSCalibur, BD Biosciences), and
data were calculated using specialized BDTM Cell Quest
and CBA software (BD Biosciences).
Also, supernatants were analyzed by Griess method
[25] in order to measure nitrite. Briefly, the supernatants
were added in triplicate to 96-well plates and mixed 1:1
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lenediamide dihydrochloride in 2.5% H3PO4. Absorbance
was read in a plate reader at 570 nm, and concentra-
tion was determined with reference to a standard curve
of sodium nitrite with concentrations ranging from 5
to 200 μmol/L.
Hormone measurement
Villous explant culture supernatants were also analyzed
for concentrations of estradiol, progesterone and HCG+ β
by an electrochemiluminescence immunoassay (ECLIA)
intended for use on an automated analyzer Cobas e 411
(Roche Diagnostics GmbH, Mannhein, Germany), accord-
ing to the manufacturer’s instructions. The limit of detec-
tion of the assays was 5.0 pg/mL for estradiol, 0.03 ng/mL
for progesterone and 0.01mUI/mL for HCG + β.
Measurement of villous explant protein content
Frozen villous explants were homogenized in radioimmu-
noprecipitation assay buffer (50 mM Tris hydrochloride,
150 mM NaCl, 1% (v/v) Triton X-100, 1% (w/v) sodium
deoxycholate and 0.1% (w/v) SDS; pH 7.5) plus a protease
inhibitor cocktail (Roche Diagnostics). Homogenate was
centrifuged at 15,000 × g for 15 min at 4°C. Supernatants
were used for protein content measurement using the
Bradford method [26]. To normalize explants from differ-
ent sizes, a ratio between cytokine production (pg/mL) and
its corresponding protein content (mg/mL) was calcu-
lated, and the data were expressed in picograms/milligram
(pg/mg) as previously proposed [21]. Likewise, concen-
trations of estradiol, progesterone, and HCG + β were
normalized according to the corresponding protein con-
tent of villous explants, and the data were expressed in
pg/mg, ng/mg and mIU/mg, respectively.
Statistical analysis
Data were expressed as mean ± standard error of mean
(SEM), and the differences between groups were determined
using ANOVA (with correction for multiple compari-
sons via the Bonferroni method) or a Student t-test,
when appropriate (GraphPad Prism Sofware 5.0 GraphPad
Software, Inc., San Diego, CA, USA). Differences were
considered statistically significant when P < 0.05. Six
independent experiments were performed in triplicate
using 24 placental tissues.
Results
Antibiotic cytotoxicity is dose dependent
The degree of cytotoxicity of different doses of antibiotics
was evaluated by measuring LDH release in villous explant
culture supernatants. T. gondii infection induced greater
LDH release and increased cytotoxicity compared to unin-
fected villous explants (Figure 1A; ANOVA, P < 0.001).
Both drugs at concentrations of 200 or 1000 μg/mL did notcause significant cytotoxicity in villous explants compared
to untreated villous explants, regardless of T. gondii in-
fection (Figure 1B). However, infected villous explants
showed a large increase in cytotoxicity when treated
with 5000 μg/mL of PSA compared to untreated villous
explants (Figure 1B). Therefore, the concentrations of 200
and 1000 μg/mL were used in further experiments.
Azithromycin and PSA are able to control T. gondii
infection in villous explants
Treatment with either azithromycin or PSA significantly
reduced intracellular proliferation of T. gondii at both
tested concentrations (200 and 1000 μg/mL) compared to
untreated villous explants (Figure 2A; ANOVA, P < 0.001).
In addition, treatment with either drug did not induce mor-
phological alterations in villous explants (Figure 2, B to E).
It was observed syncytiotrophoblast covering the chorionic
villus, the cytotrophoblast and mesenchymal tissue.
Treatment with azithromycin increases IL-6 production by
T. gondii-infected villous explants
Given the efficiency of both treatments in control of
parasitic infection, we next investigated whether antibiotic
treatments were able to alter cytokine production by villous
explants. Analyses of cytokine levels showed that azithro-
mycin and PSA treatments at 200 and 1000 μg/mL did not
alter TNF-α, IL-17A or TGF-β1 production by infected
villous explants compared to untreated/infected controls
(NT) (Figure 3, A to C; ANOVA, P < 0.001). However, a
decrease in the T. gondii proliferation in villous explants
treated with either drug was observed.
T. gondii-infected villous explants produced lower levels
of IL-10 and a significant increase of IL-12 after treatment
with PSA at both concentrations. Decreased IL-10 levels
and increased IL-12 levels matched with reduced parasite
load (Figure 3, D and E; ANOVA, P < 0.001).
When infected villous explants were treated with
azithromycin at 200 μg/mL, an increase in IL-6 levels
was observed relative to untreated/infected controls
(Figure 3F; ANOVA, P < 0.001). IL-2, IFN-γ and IL-4 levels
were not detectable in any culture supernatants.
T. gondii infection increases estradiol, progesterone and
HCG + β production in villous explants and antibiotic
treatment downmodulates these hormones
In order to better understand the action of antibiotics on
the physiology of villous explants, we conducted a second
set of experiments to determine whether T. gondii infection
is able to alter the hormonal production profile during
treatment with azithromycin or PSA. Increased secretion
of estradiol, progesterone and HCG+ β in supernatants of
T. gondii-infected villous explants was observed compared
to their respective controls (Figure 4, A to C; ANOVA,
P < 0.001). However, when infected villous explants were
Figure 1 Analysis of cytotoxicity in human villous explants. Villous explant supernatants were collected and lactate dehydrogenase (LDH)
activity was measured using the LDH Liquiform kit. The positive control was established by adding 0.2% Triton X-100 (A). Human villous explants
were infected or not by T. gondii and treated with increasing concentrations of azithromycin or PSA for 24 h and the percentage of tissue toxicity
was analyzed (B). Data are expressed as mean ± SEM. Significant differences were analyzed by ANOVA and Bonferroni multiple comparison post
hoc test. ***P < 0.001 in relation to the positive control; ΦΦ P <0.01 between uninfected and infected villous explants.
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estradiol and HCG+ β was concomitant with a decrease in
parasite load (Figure 4, D to F; ANOVA, P < 0.001). PSA
treatment of T. gondii-infected villous explants induced a
significant decrease in estradiol and progesterone compared
to infected/untreated controls (Figure 4, D to F, ANOVA,
P < 0.001). Simultaneously, there was a reduction in parasite
load. In contrast, the effects of PSA on HCG+ β secretion
showed a significant reduction in the hormone secretion
with respect of infected untreated explants, although no
difference was observed between the two concentrations
tested. However, PSA treatment reduced the parasite load.
Pretreatment of T. gondii tachyzoites with azithromycin
or PSA reduces infection in villous explants
The direct effect of azithromycin or PSA on parasites was
subsequently investigated. T. gondii 2 F1 tachyzoites were
pretreated with different concentrations (50, 100, 200 and1000 μg/mL) of the two drugs (Figure 5). Azithromycin
and PSA pretreatment at all concentrations reduced
proliferation of T. gondii compared to controls, but a dose-
dependent relationship was only observed for azithromycin
(Figure 5; ANOVA, P < 0.05), suggesting a direct action on
the parasite.
Production of nitrite
No production of nitrite was detected in supernatants from
villous explants in all experiments, suggesting that nitrogen
monoxide (NO) is not involved in the reduction of parasite
load in this experimental design.
Discussion
The conventional treatment for toxoplasmosis in pregnant
women is based on administration of spiramycin or a
combination of pyrimethamine, sulfadiazine and folinic
acid (PSA) in cases of fetal infection [23]. Pyrimethamine
Figure 2 T. gondii intracellular proliferation in villous explants treated with azithromycin or PSA. Villous explants were infected and
treated for 72 h with azithromycin or PSA at different concentrations. T. gondii proliferation was measured by a colorimetric β-galactosidase assay
(A). The bars represent mean ± SEM. Data were analyzed by ANOVA and Bonferroni multiple comparison post hoc test. Significant differences in
comparison with untreated villous explants are labeled (***P < 0.001; **P <0.01). Representative photomicrographs of human villous explants
infected or not with T. gondii: uninfected human villous explants as a negative control (B), arrows indicate tachyzoites in untreated human villous
explants (C), azithromycin-treated (D) and PSA-treated (E) human villous explants. Arrowheads indicate syncytiotrophoblast layers, and M indicates
mesenchymal tissue. Counterstaining with Mayer’s hematoxylin was performed. Scale bar: 10 μm.
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used during the first trimester of pregnancy [8]. Thus, it is
essential to develop new drugs, as well as new therapeutic
approaches, for the treatment of congenital toxoplasmosis.
Here, we showed that azithromycin is as effective as
PSA treatment of human placental villous infected
with T. gondii.
Drug dosages used (200 and 1000 μg/mL for both
azithromycin and PSA) were selected on the basis oflowest cytotoxicity, which was indirectly assessed by re-
lease of LDH. Both azithromycin and PSA were able to
reduce T. gondii proliferation at both tested concentra-
tions (200 and 1000 μg/mL). These data are in agreement
with our previous studies, where azithromycin treatment
was able to control T. gondii infection in human tropho-
blast BeWo cells [19]. Additionally, azithromycin also
showed a protective role against the ME49 strain of
T. gondii in rodent C. callosus, reducing vertical transmission
Figure 3 Cytokine production by T. gondii-infected villous explants after treatment with azithromycin or PSA. Supernatants of villous
explants were collected after 24 h of treatment and production of TNF-α (A), IL-17A (B), TGF-β1(C), IL-10 (D), IL-12 (E) and IL-6 (F) were measured
by a CBA or ELISA. The continuous line represents the parasite load. Data are expressed as mean ± SEM. Data were analyzed by ANOVA and
Bonferroni multiple comparison post hoc test. ###P < 0.001; ##P < 0.01 and #P < 0.05 in relation to NT control.
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tachyzoites and bradyzoites of T. gondii decreased
significantly compared to untreated or PSA-treated
C. callosus, demonstrating the effectiveness of azithromycintreatment [18]. In another study, azithromycin also
reduced T. gondii infection in maternal brains and
fetal eyes in a C. callosus model of congenital toxo-
plasmosis [27].
Figure 4 (See legend on next page.)
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Figure 4 Detection of sex hormones and parasite load in uninfected and T. gondii-infected villous explants, treated or not with
azithromycin or PSA. Estradiol (A), progesterone (B) and HCG + β (C) were measured by an electrochemiluminescence immunoassay of uninfected
or T. gondii-infected villous explants. Levels of (D) estradiol, (E) progesterone, and (F) HCG+ β in azithromycin- or PSA-treated or untreated villous ex-
plants were analyzed in relation to parasite load. Data were analyzed by ANOVA and Bonferroni multiple comparison post hoc test. Comparisons are
represented by symbols: parasitism, ***P < 0.001, **P < 0.01, *P < 0.05 and sexual hormones, ###P < 0.001, ##P < 0.01, #P < 0.05 in relation to NT control.
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trimesters of pregnancy and does not have teratogenic
effects [17,28,29]. A recent study demonstrated hopeful
results in the treatment of congenital toxoplasmosis by
maternal oral administration of azithromycin in addition
to sulfadoxine, pyrimethamine and acetylspiramycin in a
case of severe symptomatic fetal toxoplasmosis [7].
We observed that T. gondii infection reduced significantly
the IL-6 production when compared to untreated and un-
infected villous explants, while azithromycin treatment in
uninfected villous explants did not alter the IL-6 produc-
tion (data not shown). However, the level of this cytokine
was restored when the infected villous explants were
treated with azithromycin. In addition, azithromycin
treatment did not alter the production of TNF-α, IL-17A,
TGF-β1, IL-10 or IL-12 cytokines. Macrolide antibi-
otics not only have antibacterial activity, but also anti-
inflammatory activity and immunomodulatory effects
[30]. Previous studies from our group have shown that
azithromycin treatment induces an anti-inflammatory
response in trophoblastic cells infected by T. gondii
[19]. However, in the present work, we observed changes
only in IL-6 levels, without any variation in the cytokine
profile when T. gondii-infected villous explants were treated
with azithromycin. Some studies have demonstrated theFigure 5 T. gondii intracellular proliferation in villous explants infecte
measured by a colorimetric β-galactosidase assay. The bars represent mean
comparison post hoc test. ***P < 0.001, **P < 0.01 and *P < 0.05 in relation to
different concentrations of azithromycin (P < 0.05).suppressor effect of azithromycin in the IL-6 produc-
tion. Azithromycin reduced significantly the IL-6 release
in macrophages [31-33] and in the serum of pregnant
women infected by Chlamydia trachomatis [15], evi-
dencing the anti-inflammatory role of this drug in
many experimental models. Some undesirable effects
of the anti-inflammatory activity of macrolides include
human gingival cells when treated with azithromycin
or erythromycin showed no inhibition of matrix metal-
loproteinase 9 or CXCL8 [34]. Furthermore, clarithro-
mycin or azithromycin has not a beneficial effect on
CXCL8 release by human whole blood cells and alveo-
lar macrophages [35]. These data suggest that the anti-
inflammatory action of azithromycin is dependent on
cell type and microenvironment. Furthermore, there is
evidence that IL-6 plays an important role in resistance
to T. gondii infection [36,37]. In addition, this cytokine
participates in migration and invasion of trophoblasts
into the endometrium [38], inducing release of HCG + β
in BeWo cells [39] and other models of human tropho-
blast [40]. On the other hand, increased levels of IL-6
are involved in several aspects of pathogenesis during
pre-eclampsia [41].
Conversely, PSA treatment reduced production of IL-10
and increased IL-12 levels. These results suggest ad with pretreated (azithromycin or PSA) parasites. Proliferation was
± SEM. Data were analyzed by ANOVA and Bonferroni multiple
NTp control. Φ Comparison between villous explants treated with
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though we did not detect production of IFN-γ. During
pregnancy, induction of a type-2 immune response has no
effect on the pregnancy; however, induction of a type-1 re-
sponse by parasitic infection can lead to abortion via alter-
ation of the cytokine profile in the fetal-maternal interface
[42]. In murine models of congenital toxoplasmosis, an im-
balance in cytokine production and increased inflammatory
responses are associated with increased apoptosis and ne-
crosis at the site of implantation, leading to embryonic loss
[43].
In the present study, we showed that T. gondii infec-
tion increased production of estradiol, progesterone
and HCG + β in villous explants. Azithromycin did not
alter the estradiol, progesterone or HCG + β release in
uninfected villous, while PSA increased only estradiol
and progesterone production at the same condition
(data not shown). Thus, these findings demonstrated
that azithromycin did not alter the normal hormone
profile. In addition, treatment with azithromycin or PSA
was able to reduce secretion of these hormones when
compared to infected but untreated tissues. It has been
described that for some parasitic diseases, as leishman-
iasis, toxoplasmosis and malaria, increased levels of
progesterone and glucocorticoid are associated with
decreased resistance in murine experimental models
[44-46]. In mice, increased morbidity during toxoplas-
mosis has been associated with estradiol levels, while
gonadectomy reduces pathogenesis of toxoplasmosis
[3]. A high concentration of progesterone has also been
shown to increase susceptibility to T. gondii infection
during pregnancy by suppressing production of IL-12
and IFN-γ [47] and, therefore, suppressing a type-1 re-
sponse utilizing the progesterone and glucocorticoid re-
ceptors [48]. In the present work, increased production
of hormones by T. gondii-infected villous explants may
be a result of an evasion strategy orchestrated by the
parasite. Recent works have demonstrated that hormones
are deeply involved in the regulation of parasite load
both modulating the host immune-endocrine network
and parasite proliferation [49]. Thus we hypothesized
an indirect action of the drug treatment inducing lower
parasite load that in turn decreased hormones secretion.
We showed that T. gondii-infected villous explants, treated
or untreated, failed to induce NO production. A previous
study has demonstrated that human villous explants as well
BeWo trophoblast cells infected with T. gondii were unable
to release NO [21,50]. In our experimental design, reduc-
tion of parasite load after antibiotic treatment was likely
not related to NO.
Our results also showed that pretreatment of parasites
with azithromycin or PSA was able to reduce proliferation
of T. gondii in villous explants. Azithromycin targets the
70S ribosomal subunit of susceptible microorganisms,such as P. falciparum and P. vivax, interfering with pro-
tein synthesis of the parasites [17]. Additionally, parasites
from the Apicomplexa phylum have a plastid called apico-
plast, which is a target site for binding of diverse drugs
with antiparasitic activity [51,52]. On the other hand,
blocking the activities of the plastid does not typically re-
sult in immediate death of parasites, including T. gondii.
In contrast, the parasiticidal activity of plastid inhibitors is
only detected when tachyzoites attempt to establish infec-
tion within a new host cell [17,53].
Conclusion
The present study demonstrated that azithromycin is able
to control T. gondii infection in human villous explants
from the third trimester of pregnancy, providing evidence
that it may be an effective alternative drug for treatment
of congenital toxoplasmosis by reducing the proliferation
rate of T. gondii. Further clinical studies need to be con-
ducted to validate the present findings and to enable new
therapeutic approaches for the treatment of T. gondii
infection at the fetal-maternal interface.
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